A teratoma is associated with malignant nongerm cell tumors in 3 to 6% of patients with metastatic GCT who are treated with platinum-based CHT.
A teratoma is associated with malignant nongerm cell tumors in 3 to 6% of patients with metastatic GCT who are treated with platinum-based CHT. [1] [2] [3] A derivation from preexistent mesenchymal elements of the teratomatous tissue is assumed. 4 Alternatively, the nongerm tissue may arise from the malignant transformation of totipotential germ cell subpopulations showing partial differentiation into somatic mesenchymal tissue. 5 Up to 80% of patients present with metastases. 4 Most nongerm cell malignancies associated with GCT are sarcomas, rhabdomyosarcoma being the most common subtype. 6 Sarcomas can be present in the primary tumor or appear in metastases. 1, 7 Teratomas with rhabdomyosarcomatous differentiation have a poor prognosis. 4 Here, we report a rare case of a combination of seminoma, teratoma and rhabdomyosarcoma. To our knowledge, this is the first report of successful treatment of a metastasized teratoma with rhabdomyosarcomatous differentiation, with HD-CHT and APBSCT.
Case report
A 51-year-old man with a left testicular mass underwent inguinal orchidectomy in November 1996. Histologically, the tumor was a combined seminoma, partially immature teratoma and rhabdomyosarcoma. Biopsy of the right testis revealed no malignancy. AFP and ␤HCG serum levels were normal. Retroperitoneal lymph node dissection was performed 3 weeks later due to the unfavorable histology and revealed no evidence of malignant spread.
Three months later, the patient was admitted to our hospital because of generalized seizures. There was a 4-week history of back pain, appetite loss, nausea, vomiting, and lethargy. On physical examination, the patient was somnolent but there were no other significant abnormalities. CT scan of the brain and lumbar puncture yielded normal findings. Hematologic and blood chemical tests showed an elevated creatinine (489 mol/l; normal 58-110 mol/l), lactate dehydrogenase (1099 U/l; normal 120-240 U/l), and calcium (4.0 mmol/l; normal 2.24-2.78 mmol/l). A bone scan revealed no radiolabeled technetium uptake. Cytologic and histologic BM examination showed massive rhabdomyosarcoma involvement (Figure 1a) , which was confirmed by histochemical stains positive for muscle-specific antigen and desmin ( Figure 1b) . MRI of the vertebral column revealed multiple spots with low signal intensity in T1-and high signal intensity in T2-weighted images typical of tumor infiltration (Figure 2a) . A solitary metastasis was found in the liver.
Infusions of normal saline, furosemide, steroids, and pamidronate were given. CHT with 50 mg/m 2 epirubicin for 1 day, etoposide 250 mg/m 2 , 2000 mg/m 2 ifosfamide, and 25 mg/m 2 cisplatin for 2 days each was initiated. The patient regained normal conciousness, and calcium and creatinine levels returned to normal. Four CHT courses were given (total epirubicin dose 200 mg/m 2 ) and 90 mg pami- 
Discussion
The prognosis of patients with GCT with nongerm malignant transformation is poorer than in pure GCT with a recurrence rate of up to 86% and an overall survival (OS) rate of only 58% to 65%. [1] [2] [3] The median OS in one retrospective study was 23 months. 4 Complete surgical resection of residual or recurrent disease is recommended when feasible. 1, 4, 6 The role of CHT has not been well defined. The CR rate was estimated at 30% for CHT alone, and at 38% for CHT and surgery. 6 Patients with a mediastinal tumor, neural or rhabdomyosarcomatous differentiation and distant metastases usually have the shortest survival. 4, 6 Diffuse BM metastases with hypercalcemia are a very rare manifestation of these tumors.
There are only a few reports of the treatment and outcome in patients with a teratoma and a rhabdomyosarcoma. The four patients from the series of Comiter et al 4 underwent CHT in addition to surgery. Three patients relapsed: one patient died of PD after 7 months, two patients were still alive with the disease after 47 and 72 months and one patient was in CR after 49 months. Ulbright et al 1 reported on four patients treated by surgery and CHT with procarbazine, vincristine and BCNU, combined with doxorubicin in one patient and etoposide in another. Two patients died of PD after 15 and 39 months and two were still alive 33 months after additional surgery: one in PD and one in CR. Ritchey et al 8 reported a patient with a metastatic teratoma and a rhabdomyosarcoma and chondrosarcoma who was still alive 12 months after complete excision of the tumor. Terrier-Lacombe et al 9 described a patient with a testicular teratoma and an embryonal rhabdomyosarcoma who developed lymph node metastases 10 months after orchidectomy. The metastases responded completely to vincristine, dactinomycin and ifosfamide and to subsequent cisplatin-based CHT. Six months later, he developed metastases, which partially responded to two cycles of ifosfamide and cisplatin. The patient was in PR after 3 months of follow-up. 9 The combination of seminoma, teratoma and rhabdomyosarcoma is very rare. To our knowledge, there is only one report involving a Japanese patient. 5 The non-metastasized tumor was treated by orchidectomy, one cycle of vincristine, dactinomycin and cyclophosphamide, as well as local irradiation. The patient was in CR 39 months after surgery.
The outcome of our patient was favorable despite a rhabdomyosarcomatous component and metastastatic, unresectable disease. This may be due to the unconventional regimen primarily directed against the rhabdomyosarcoma, but also including therapy elements against GCT. The rhabdomyosarcomatous component of the tumor was considered prognostically decisive as the more malignant one. Moreover, a metastastatic GCT component was not detected. The combination of epirubicin and ifosfamide achieved a 45-60% response rate in metastasized soft tissue sarcoma. 10 The GCT component was targeted with cisplatin, ifosfamide, and etoposide. The use of cisplatin and ifosfamide has been well established in GCT. In our patient, cisplatin was administered at 50% of the regular dose because of impaired renal function. In addition, etoposide has proven beneficial in disseminated GCT.
11
HD-CHT with ASCT improves survival in patients with relapsed and/or refractory GCT. 12 The role of HD-CHT in soft tissue sarcoma is not established; however, promising results using HD-CHT in first remission have been recently reported. In 26 children with poor-risk soft tissue sarcoma, including 21 patients with rhabdomyosarcoma and 14 with primary metastatic disease, a 2-year OAS of 56% was reached after HD-CHT with melphalan and etoposide. 13 In 30 adult patients with metastatic or locally advanced, unresectable soft tissue sarcoma, the OAS at 5 years after HD-CHT using ifosfamide, etoposide, and cisplatin was 23%. 14 Experience with HD-CHT has not yet been reported for patients with high-risk mixed GCT. In view of recent results with this treatment in soft tissue sarcoma we assume a beneficial effect of HD-CHT in our patient. We added epirubicin to our HD-CHT regimen although it is usually not included in high-dose regimens because of its non-marrow dose-limiting toxicity. However, in our case, it was feasible and may have even been beneficial.
Our case report emphasises that tumor-adapted CHT including HD-CHT with ASCT can induce long-term remission in high-risk patients with transformed GCT.
